Results 81 to 90 of about 25,460 (223)

Third‐Line Overactive Bladder Treatments: Cost–Benefit Analysis in an Australian Public Hospital

ANZ Journal of Surgery, EarlyView.
ABSTRACT Introduction and Objectives To review the efficacy and cost‐effectiveness of third‐line overactive bladder (OAB) managements, including percutaneous tibial nerve stimulation (PTNS), intravesical botulinum toxin A (Botox) and sacral neuromodulation (SNM) in the urology department of a tertiary public hospital.
Rowan Klein Nulend, Marco Rosario, Dale Wood, Lawrence Kim, Audrey Wang   +4 more
wiley   +1 more source

Pain during ice water test distinguishes clinical bladder hypersensitivity from overactivity disorders

BMC Urology, 2006
Background The Bladder cooling reflex (BCR) i.e. uninhibited detrusor contractions evoked by intravesical instillation of cold saline, is a segmental reflex believed to be triggered by menthol sensitive cold receptors in the bladder wall, with the ...
Bountra Chas, Chessell Iain P, Waters Janet, Mukerji Gaurav, Agarwal Sanjiv K, Anand Praveen   +5 more
doaj   +1 more source

Alkalinised lidocaine as an anaesthetic before onabotulinumtoxinA injections. a randomised trial

BJU International, Volume 135, Issue 4, Page 638-647, April 2025.
Objectives To evaluate the effect of intravesical alkalinised lidocaine as an anaesthetic treatment on procedural pain during intradetrusor onabotulinumtoxinA (BTX‐A) injections for overactive bladder. Patients and Methods This single‐centre, randomised, double‐blind, placebo‐controlled two period crossover trial was conducted on women scheduled for ...
Meryam El Issaoui, Marlene Elmelund, Niels Klarskov   +2 more
wiley   +1 more source

Human idiopathic and neurogenic overactive bladders and the role of M2 muscarinic receptors in contraction

, 2007
Objectives: This study examines whether M2 receptors contribute to direct contraction of the detrusor in human neurogenic and idiopathic overactive bladders.
Stevens, Laurie A., Chapple, Christopher R., Chess-Williams, Russ   +2 more
core   +1 more source

Mirabegron for Overactive Bladder: A Novel, First-in-Class β3- Agonist Therapy

Urology Journal, 2013
Purpose: To discuss the pharmacotherapeutic aspects of Mirabegron which is a first-inclassnovel β3 receptor agonist drug recently approved by the food and drug administration(FDA) for the treatment of overactive bladder (OAB).Materials and Methods: We ...
Mohammed Imran, Abul Kalam Najmi, Shams Tabrez   +2 more
doaj  

β3‐Adrenoceptor Agonists for Neurogenic Lower Urinary Tract Dysfunction: Evidence and Clinical Rationale for First‐Line Therapy

Neurourology and Urodynamics, Volume 45, Issue 8, Page 1476-1478, November 2026.
ABSTRACT Aims To summarize current evidence on β3‐adrenoceptor agonists for managing neurogenic lower urinary tract dysfunction (NLUTD), focusing on their efficacy, safety, and clinical role in optimizing bladder storage and protecting upper tracts. Methods Evidence from randomized controlled trials, meta‐analyses, and observational studies in spinal ...
Sharon E. Fishberg, Rano Matta
wiley   +1 more source

Botulinum Toxin A for Idiopathic Detrusor Overactivity

Annals of the Academy of Medicine, Singapore, 2010
Introduction: This prospective study aims to evaluate botulinum toxin type A (BTX-A, Botox®) as a treatment for idiopathic detrusor overactivity (IDO) for patients with symptoms of overactive bladder (OAB). Materials and Methods: Nineteen patients with IDO were treated with intradetrusal injection of 200 units of BTX-A under cystoscopic guidance. There
Kwok Ying, Lie, Michael Y C, Wong, Lay Guat, Ng   +2 more
openaire   +2 more sources

“What Medical Management Should Be First Line for Bladder Storage Symptoms in NLUTD”—Pro Botox

Neurourology and Urodynamics, Volume 45, Issue 8, Page 1479-1481, November 2026.
ABSTRACT Objectives Neurogenic lower urinary tract dysfunction (NLUTD) severely impairs patient quality of life (QoL). While oral medications are often first‐line treatments, their high failure rates and side effects limit their effectiveness. Thus, we argue for the use of intravesical botulinum toxin A (BoNT‐A) injections as a first‐line alternative ...
Vada Furlan, Alyssa Kobayashi, Zhina Sadeghi   +2 more
wiley   +1 more source

The Use of Botulinum Toxin A in Idiopathic Overactive Bladder Syndrome

, 2010
Overactive bladder syndrome continues to be a significant burden for the general population. Current first-line medical therapy often includes antimuscarinic medications designed for overactive bladder. Poor efficacy and significant side effects of these
Angelo Gousse, Gousse, Angelo, Gomez, Christopher S, Prashanth Kanagarajah, Kanagarajah, Prashanth, Christopher S. Gomez   +5 more
core   +1 more source

Intermittent urgency-activated, transcutaneous tibial nerve stimulation: Feasibility and urodynamic effects in overactive bladder

Continence
This short report extends our previous proof-of-concept on intermittent, urgency-activated transcutaneous tibial nerve stimulation (TTNS) during invasive cystometry.
Javier A. Muñoz, John PFA. Heesakkers, Diego Leiva, Joaquín O. García, Pablo A. Gálvez   +4 more
doaj   +1 more source